Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Teresa Roberts

Nurse Practitioner, Psychiatric/Mental Health Fort Wayne, IN Nurse Practitioner

NPI 1184911158 CMS profile 11072125

909 E State Blvd, Fort Wayne, IN 46805

Open in the dashboard

General payments

$13,172

626 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Teresa Roberts of Fort Wayne, IN is reported in the CMS Open Payments database as having received $13,172 across 626 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Nurse Practitioner, Psychiatric/Mental Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,121 154
2024 General $2,650 136
2023 General $3,085 145
2022 General $2,004 87
2021 General $2,312 104

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Teresa Roberts
  • Nurse Practitioner, Psychiatric/Mental Health median
  • Middle half of Nurse Practitioner, Psychiatric/Mental Health
  • National median

In program year 2025, general payments to Teresa Roberts were reported at $3,121. Among 26,152 Nurse Practitioner, Psychiatric/Mental Health profiles paid that year, the median was $258 and the middle half received between $93 and $764.

Show as a table
Year Teresa Roberts Nurse Practitioner, Psychiatric/Mental Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $2,312 $166 $54–$482 $132
2022 $2,004 $195 $66–$559 $149
2023 $3,085 $233 $82–$673 $160
2024 $2,650 $236 $84–$688 $164
2025 $3,121 $258 $93–$764 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Otsuka America Pharmaceutical, Inc. $2,682 69 payments
  2. AbbVie, Inc. $1,441 121 payments
  3. Sunovion Pharmaceuticals Inc. $1,166 59 payments
  4. Teva Pharmaceuticals USA, Inc. $1,148 39 payments
  5. ITI, Inc. $992 47 payments
  6. Lundbeck LLC $975 95 payments
  7. Alkermes, Inc. $939 41 payments
  8. Neurocrine Biosciences, Inc. $655 28 payments
  9. E.R. Squibb & Sons, L.L.C. $644 25 payments
  10. Axsome Therapeutics, Inc. $551 13 payments
  11. Other $1,981 89 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $12,870 623 payments
  2. Education $302 3 payments
Products named General payments · program years 2021–2025
  1. REXULTI $1,828 46 payments
  2. LATUDA $1,166 59 payments
  3. ABILIFY MAINTENA $1,003 51 payments
  4. VRAYLAR $966 84 payments
  5. CAPLYTA $825 39 payments
  6. ARISTADA Cns $773 39 payments
  7. ARISTADA Cns $773 39 payments
  8. LYBALVI $733 35 payments
  9. ARISTADA Cns $638 30 payments
  10. ARISTADA Cns $638 30 payments
  11. Other $7,026 324 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 75 drugs

Part D claims

5,266

Median for Nurse Practitioner: 389

Drug cost

$1,330,965

Median for Nurse Practitioner: $21,885

Branded share of claims

25.3%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Invega Sustenna Paliperidone Palmitate Brand 142 $423,751
Abilify Maintena Aripiprazole Brand 86 $221,416
Rexulti Brexpiprazole Brand 78 $149,008
Vraylar Cariprazine Hcl Brand 76 $117,282
Austedo Deutetrabenazine Brand 17 $102,445
Aristada Aripiprazole Lauroxil Brand 14 $45,477
Trintellix Vortioxetine Hydrobromide Brand 50 $35,071
Latuda Lurasidone Hcl Brand 20 $28,140
Fetzima Levomilnacipran Hcl Brand 17 $19,810
Lurasidone Hcl Generic 97 $17,366

The 10 drugs with the highest cost, of 75 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 9 billing codes

Paid by Medicare

$12,027

Medicare's payments for the services billed

Medicare patients

111

Average age 58

Services billed

255

66 women, 45 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 56%
High blood pressure 52%
Diabetes 24%
Arthritis 24%
COPD 19%
Ischemic heart disease 16%
Chronic kidney disease 11%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
  • Otsuka America Pharmaceutical, Inc. $381
  • Lundbeck LLC $177
$558 78 —
VRAYLAR
  • AbbVie, Inc. $392
$392 76 —
Auvelity
  • Axsome Therapeutics, Inc. $254
$254 — —
CAPLYTA
  • ITI, Inc. $167
$167 — —
Austedo XR
  • Teva Pharmaceuticals USA, Inc. $166
$166 17 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

626 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Psychiatric/Mental Health in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record